Back to search
Scientific Name: Binimetinib
Brand Name: Mektovi
Company Owner: Not Available
Mechanism Of Action Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. The inhibition of MEK1/2 prevents the activation of MEK1/2-dependent effector proteins and transcription factors. This process can result in the inhibition of growth factor-mediated cell signaling. This may lead to the inhibition of tumor cell proliferation and an inhibition in the production of various inflammatory cytokines including interleukin-1, -6 and tumor necrosis factor. MEK1/2 are themselves threonine and tyrosine kinases that possess a dual specificity. They subsequently contribute critically to the activation of the RAS/RAF/MEK/ERK pathway and are typically upregulated in a number of different tumor cell types
Description of the Drug: Binimetinib is a medication used to treat metastatic melanoma with specific mutations.
Protein Data Bank:
Source: DrugBank Online – Retrieved 2023-01-23 from